Terms of Use

Translational Research & Strategic Services 

Kinexum guides, designs, and manages strategic and operational solutions to the regulatory, manufacturing, nonclinical,  clinical development, and business challenges necessary to take scientific discoveries to proof of concept and through the product life cycle.

Kinexum teams supplement the strengths of large and small organizations to reach high-value milestones effectively and efficiently.  Kinexum specializes in crafting creative but sound and integrated solutions across scientific disciplines, therapeutic areas, product modalities, and business stages. We respond to emergencies and as well as requests for problem prevention and complex long-range planning. 

 


 

News and Upcoming events

Please join our next webinar

Kinexum Webcast: PTSD–Associated Pathologies in the World of 2018

Thomas Hedberg, MSc, Ph.D, Executive Director International Medical Crisis Response Alliance, on causes, effects and treatment failure of PTSD.

Friday, 12.14.2018, at 11 a.m. ET

 



        

Tuesday, January 8th, 2019


 

If you missed our 10/26/2018 Kinexum Public Webinar, a recording is now available:

Using Metformin to Target Aging

 Featuring TAME trial co-PI's Nir Barzilai, MD, and Steve Kritchevsky, PhD



 

Recent Articles

A Perspective on the Development of the Treatment of Our Next Epidemic - Brian Harvey, MD, Ph.D

Background 

Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in the industrialized world [1]. The phenotypes of the disease extend from nonalcoholic fatty liver (NAFL) to nonalcoholic steatohepatitis (NASH), the latter of which progresses to liver fibrosis and end-stage cirrhosis [2]. 

Read More

EVIDENTIARY STANDARDS IN THE ACCELERATED APPROVAL OF CANCER DRUGS Grant Williams, MD

Let’s pretend I am an cancer drug sponsor with an immune-stimulating drug (Drug A) for the treatment of a refractory cancer. I plan to study Drug A in combination with an approved immunotherapy drug (Drug B), such as a PD1 inhibitor. 

Read more

A Crash Course on 510(k) Clearances - Michael Sharp, Ph.D

I still get asked this question 40 years after the Food, Drug and Cosmetic Act (FDCA) implemented the medical device amendment (MDA). Although the answer is more confusing than may be expected, it is important for understanding the regulatory status of medical devices.

Read more

Beyond the NIH - Other Federal Medical R&D - Dean E. Calcagni, M.D.

 Not counting the NIH, the U.S. Federal government spends more than $1.5 billion each year on medical research and development.

Read more

 

Terms of Use

This web site may contain other proprietary notices and copyright information, the terms of which must be observed and followed. Information on the site may contain technical inaccuracies or typographical errors. Kinexum may make improvements and/or changes in the information or programs described at any time without notice.

Global availability:

Information published on this site may contain references to Kinexum programs and services that are not announced or available in countries outside the United States. Such references do not imply an intent to make such products, programs, or services available in specific countries and require communication with Kinexum's corporate office for specific information.

Third-party web sites:

Kinexum makes no representation whatsoever about any other web site which may be accessed through this site, and does not accept any responsibility for the content or use of such web site.

Limited License:

Subject to the terms and conditions set forth in this agreement, Kinexum grants you a non-exclusive, limited right to access, use, and display this site and the materials thereon. You agree not to interrupt the operation of this site or its contents in any way.

Confidential information:

Kinexum does not want or require, and you should not, send any confidential or proprietary information to the Kinexum web site. You agree that any information that you or your agents provide to us are not considered confidential or proprietary and will not be in any way defamatory, threatening, obscene, harassing, or otherwise unlawful and will not include the proprietary information of another. Kinexum is free to use information available to the site as unrestricted, irrevocable, worldwide, a royalty-free license to use, reproducible for public display, transmittable, and available for distribution.

Limitation of Liability

IN NO EVENT SHALL KINEXUM OR ANY OF ITS SUBSIDIARIES OR REPRESENTATIVES BE LIABLE TO ANY INDIVIDUAL OR ENTITY FOR ANY DIRECT, INDIRECT, SPECIAL, CONSEQUENTIAL, OR OTHER INJURIES OR DAMAGES INCLUDING, WITHOUT LIMITATION, ANY LOST PROFITS, BUSINESS INTERRUPTION, LOSS OF INFORMATION OR PROGRAMS OR OTHER DATA ON YOUR INFORMATION HANDLING SYSTEM THAT ARE RELATED TO THE USE OF, OR THE INABILITY TO USE, THE CONTENT, MATERIALS, AND FUNCTIONS ON THIS SITE OR ANY LINKED WEB SITE, EVEN IF KINEXUM IS EXPRESSLY ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.

Changes:

Kinexum reserves the right, at its sole discretion, to change, modify, add, or remove any portion of this agreement, whole or in part, at any time. Kinexum may also impose limits on certain parts of the site and may terminate the authorization and/or rights of license given above.

Terms of Use

By using the Kinexum web site, you have indicated your agreement to these terms of use:

  • The materials available on this site, including materials linked from other sites, are provided without warranties of any kind, expressed or implied. Kinexum does not warrant that the materials will be error free, nor free of viruses, defamatory, offensive, or other harmful content.
  • This site is copyrighted. It is for your personal and non-commercial use. No portion of this site can be copied, modified, transmitted, distributed, or otherwise used without express permission from Kinexum or the content owners. This include use of trademarks, service marks, and trade names.
  • You agree to defend, indemnify, and hold Kinexum and our affiliates, representatives, and subsidiaries harmless from and against any and all losses, liabilities, damages, and expenses, including attorney's fees, arising out of your use of this site.